高级检索

来氟米特联合甲氨蝶呤治疗类风湿关节炎患者的疗效及对血清生长因子的影响

李艳琴, 孙强

李艳琴, 孙强. 来氟米特联合甲氨蝶呤治疗类风湿关节炎患者的疗效及对血清生长因子的影响[J]. 实用临床医药杂志, 2020, 24(21): 108-111. DOI: 10.7619/jcmp.202021031
引用本文: 李艳琴, 孙强. 来氟米特联合甲氨蝶呤治疗类风湿关节炎患者的疗效及对血清生长因子的影响[J]. 实用临床医药杂志, 2020, 24(21): 108-111. DOI: 10.7619/jcmp.202021031
shu
LI Yanqin, SUN Qiang. Efficacy of leflunomide combined with methotrexate in rheumatoid arthritis patients and its influences on serum growth factors[J]. Journal of Clinical Medicine in Practice, 2020, 24(21): 108-111. DOI: 10.7619/jcmp.202021031
Citation: LI Yanqin, SUN Qiang. Efficacy of leflunomide combined with methotrexate in rheumatoid arthritis patients and its influences on serum growth factors[J]. Journal of Clinical Medicine in Practice, 2020, 24(21): 108-111. DOI: 10.7619/jcmp.202021031
shu

来氟米特联合甲氨蝶呤治疗类风湿关节炎患者的疗效及对血清生长因子的影响

  • 陕西省汉中市中心医院 检验科, 陕西 汉中, 723000

详细信息

  • 中图分类号: R593.22

Efficacy of leflunomide combined with methotrexate in rheumatoid arthritis patients and its influences on serum growth factors

  • Department of Clinical Laboratory, Hanzhong Central Hospital in Shaanxi Province, Hanzhong, Shaanxi, 723000

摘要

    摘要
  • 摘要: 目的 观察来氟米特联合甲氨蝶呤治疗类风湿关节炎(RA)患者的疗效及血清血管内皮生长因子(VEGF)、血管内皮细胞生长因子受体2(VEGFR2)的表达变化。 方法 将110例RA患者随机分为治疗组与对照组,每组55例。对照组给予甲氨蝶呤治疗,治疗组给予来氟米特联合甲氨蝶呤治疗。治疗3个月后,评价疗效、安全性、治疗前后临床症状变化。比较2组血沉(ESR)、类风湿因子(RF)、VEGF、VEGFR2的变化。 结果 治疗组治疗总有效率为94.55%, 高于对照组的78.18%, 差异有统计学意义(P<0.05)。治疗3个月后, 2组较治疗前晨僵时间缩短,差异有统计学意义(P<0.05)。2组较治疗前关节肿胀数量、压痛关节数量减少,差异有统计学意义(P<0.05)。2组治疗后ESR、RF、VEGF、VEGFR2水平下降,差异有统计学意义(P<0.05)。治疗组晨僵时间短于对照组,差异有统计学意义(P<0.05);关节肿胀数量、压痛关节数量少于对照组,差异有统计学意义(P<0.05);ESR、RF、VEGF、VEGFR2水平均低于对照组,差异有统计学意义(P<0.05)。 结论 来氟米特联合甲氨蝶呤治疗RA安全有效,能有效改善RA临床症状,降低血清VEGF、VEGFR2水平。
    Abstract: Objective To observe the efficacy of leflunomide combined with methotrexate in the treatment of rheumatoid arthritis(RA)patients and the changes of serum vascular endothelial growth factor(VEGF)and vascular endothelial growth factor receptor 2(VEGFR2). Methods A total of 110 patients with RA were randomly divided into treatment group and control group, with 55 cases in each group. The control group was treated with methotrexate, while the treatment group was treated with leflunomide combined with methotrexate. After 3 months of treatment, the curative effect, safety and clinical symptom before and after treatment were evaluated. The levels of erythrocyte sedimentation rate(ESR), rheumatoid factor(RF), VEGF and VEGFR2 were compared between the two groups. Results The total effective rate of the treatment group was significantly higher than that of the control group(94.55% versus 78.18%, P<0.05). After 3 months of treatment, morning stiffness time in the two groups was significantly shorter than that before treatment(P< 0.05). The number of joint swelling and tenderness in the two groups were significantly reduced than those before treatment(P< 0.05). The levels of ESR, RF, VEGF and VEGFR2 after treatment in the two groups were significantly lower(P< 0.05). The morning stiffness time in the treatment group was significantly shorter than that in the control group(P< 0.05). The number of joint swelling and tenderness in the treatment group were significantly less than those in the control group(P< 0.05). The levels of ESR, RF, VEGF and VEGFR2 in the treatment group were significantly lower than those in the control group(P< 0.05). Conclusion Leflunomide combined with methotrexate is safe - and effective in the treatment of RA, which can effectively improve the clinical symptoms of RA, andreduce the levels of serum VEGF and VEGFR2.
    • HTML全文
    • 参考文献(15)

  • Kohno Y, Mizuno M, Ozeki N, et al. Comparison of mesenchymal stem cells obtained by suspended culture of synovium from patients with rheumatoid arthritis and osteoarthritis[J]. BMC Musculoskelet Disord, 2018, 19(1): 78.
    马凤云, 庞琳娜, 孙聪慧. 小剂量糖皮质激素联合甲氨蝶呤在类风湿关节炎达标治疗中应用及对患者血清TNF-a的影响[J]. 湖南师范大学学报: 医学版, 2018, 15(1): 28-30.
    杨茹, 张祎, 刘志纯. 甲氨蝶呤联合来氟米特治疗类风湿关节炎效果观察[J]. 山东医药, 2018, 58(6): 91-92.

    Kendrew J, Eberlein C, Hedberg B, et al. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding[J]. Mol. Cancer Ther., 2011, 10(5): 770-783.
    郑善翠, 刘磊, 孙学明, 等. 血管内皮生长因子在类风湿性关节炎发病机制中的研究进展[J]. 中国医师进修杂志, 2018, 41(10): 957-960.
    徐丽玲, 苏茵. 2015年美国风湿病学会类风湿关节炎的治疗指南[J]. 中华风湿病学杂志, 2016, 20(1): 69-70.
    中华人民共和国卫生部. 新药中药临床研究指导原则(第1辑)[M]. 1993: 212-215.
    谢李, 邹庆华, 石颖, 等. 艾拉莫德联合MTX对难治性类风湿关节炎患者IL-1、血清TNF-α、VEGF水平的影响[J]. 贵州医药, 2018, 42(7): 831-832.
    王洪涛, 张凤, 张玲玲. 来氟米特联合甲氨蝶呤治疗类风湿关节炎50例[J]. 医药导报, 2018, 37(8): 948-951.
    杨波, 杨正国, 王霜, 等. 甲氨蝶呤联合来氟米特对类风湿关节炎患者炎症因子和免疫球蛋白的影响[J]. 现代生物医学进展, 2018, 18(18): 3463-3466

    , 3528.
    郑锡铭, 张涛, 张爱君, 等. 抗环瓜氨酸肽抗体与风湿四项联合检测对类风湿关节炎的诊断价值[J]. 宁夏医科大学学报, 2015, 37(1): 17-21.

    Malemud C J. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis[J]. Clin Chim Acta, 2007, 375(1/2): 10-19.

    Paradowska-Gorycka A, Pawlik A, Romanowska-Prochnicka K, et al. Relationship between VEGF gene polymorphisms and serum VEGF protein levels in patients with rheumatoid arthritis[J]. PLoS One, 2016, 11(8): e0160769.
    刘敏, 王培蓉, 马方伟, 等. 雷公藤多苷治疗类风湿性关节炎的临床观察及对血清VEGF、VEGFR2表达水平的影响研究[J]. 陕西中医, 2016, 37(1): 72-74.
    王医林, 王健, 刘英纯, 等. 甲氨蝶呤联合来氟米特治疗类风湿性关节炎的疗效及对血清 CRP、IL-8及 TNF-α水平的影响[J]. 现代生物医学进展, 2017, 17(36): 7146-7150.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量: 
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-04
  • 网络出版日期:  2020-12-21
  • 发布日期:  2020-11-23

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计